EMEA-001222-PIP01-11-M01 - paediatric investigation plan

Olokizumab

Key facts

• Active substance:
  Olokizumab
• Therapeutic area:
  Musculoskeletal and connective tissue disorders
• Decision number:
  P/0208/2024
• PIP number:
  EMEA-001222-PIP01-11-M01
• Pharmaceutical form(s):
  Solution for injection
• Condition(s) / indication(s):
  Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic arthritis)
• Route(s) of administration:
  Subcutaneous use
• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  14/06/2024
• Compliance check done:
  No

Decision

P/0208/2024: EMA decision of 14 June 2024 on the acceptance of a modification of an agreed paediatric investigation plan for olokizumab (EMEA-001222-PIP01-11-M01)

Adopted